Lucocq, J; Haugk, B; Joseph, N; Hawkyard, J; White, S; Mownah, O; Menon, K; ... Pandanaboyana, S; + view all Lucocq, J; Haugk, B; Joseph, N; Hawkyard, J; White, S; Mownah, O; Menon, K; Furukawa, T; Inoue, Y; Hirose, Y; Sasahira, N; Mittal, A; Samra, J; Sheen, A; Feretis, M; Balakrishnan, A; Ceresa, C; Davidson, B; Pande, R; Dasari, BVM; Tanno, L; Karavias, D; Helliwell, J; Young, A; Nunes, Q; Urbonas, T; Silva, M; Gordon-Weeks, A; Barrie, J; Gomez, D; Van Laarhoven, S; Nawara, H; Doyle, J; Bhogal, R; Harrison, E; Roalso, M; Zaharia, C; Ciprani, D; Aroori, S; Ratnayake, B; Koea, J; Capurso, G; Bellotti, R; Stättner, S; Alsaoudi, T; Bhardwaj, N; Jeffery, F; Connor, S; Cameron, A; Jamieson, N; Roberts, K; Soreide, K; Gill, AJ; Pandanaboyana, S; - view fewer (2024) Invasive intraductal oncocytic papillary neoplasms (IOPN) and adenocarcimoma arising from intraductal papillary mucinous neoplasms (A-IPMN) of the pancreas: comparative analysis of clinicopathological features, patterns of recurrence and survival: a multicentre study. HPB , 26 (11) pp. 1421-1428. 10.1016/j.hpb.2024.07.410.

Text Invasive intraductal oncocytic papillary neoplasms (IOPN) and adenocarcimoma arising from intraductal papillary mucinous neoplasms (A-IPMN)_AAM.pdf - Accepted Version Access restricted to UCL open access staff until 1 November 2025. Download (1MB)

Abstract

Background: Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreas are now considered a separate entity to intraductal papillary mucinous neoplasms (IPMN). Invasive IOPNs are extremely rare, and their recurrence patterns, response to adjuvant chemotherapy and long-term survival outcomes are unknown. // Methods: Consecutive patients undergoing pancreatic resection (2010–2020) for invasive IOPNs or adenocarcinoma arising from IPMN (A-IPMN) from 18 academic pancreatic centers worldwide were included. Outcomes of invasive IOPNs were compared with A-IPMN invasive subtypes (ductal and colloid A-IPMN). // Results: 415 patients were included: 20 invasive IOPN, 331 ductal A-IPMN and 64 colloid A-IPMN. After a median follow-up of 6-years, 45% and 60% of invasive IOPNs had developed recurrence and died, respectively. There was no significant difference in recurrence or overall survival between invasive IOPN and ductal A-IPMN. Overall survival of invasive IOPNs was inferior to colloid A-IPMNs (median time of survival 24.4 months vs. 86.7, months, p = 0.013), but the difference in recurrence only showed borderline significance (median time to recurrence, 22.5 months vs. 78.5 months, p = 0.132). Adjuvant chemotherapy, after accounting for high-risk features, did not reduce rates of recurrence in invasive IOPN (p = 0.443), ductal carcinoma (p = 0.192) or colloid carcinoma (p = 0.574). // Conclusions: Invasive IOPNs should be considered an aggressive cancer with a recurrence rate and prognosis consistent with ductal type A-IPMN.

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as XMLCSVJSON

Archive Staff Only

View Item